Stockscreener 앱 받기
2.44
4.67%
-0.13
전일 마감가:
$2.57
열려 있는:
$2.52
하루 거래량:
63,597
Relative Volume:
0.04
시가총액:
$4.82M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.8106
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
-16.38%
1개월 성능:
+6.99%
6개월 성능:
-68.71%
1년 성능:
-70.89%
1일 변동 폭
$2.42
$2.53
1주일 범위
$2.42
$3.24
52주 변동 폭
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
2.45 | 4.82M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.96 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.12 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.39 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.53 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Ensysce Biosciences (ENSC) to Release Earnings on Friday - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Ensysce Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire
Ensysce Biosciences Inc (ENSC) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Ensysce Biosciences Secures $2.2M Funding Boost: Key Details on TAAP/MPAR Program Advancement - Stock Titan
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Ensysce Biosciences announces exercise of warrants for $2.2M gross proceeds - MSN
For Array Technologies Inc [ARRY], Analyst sees a rise to $7. What next? - dbtnews.com
Ensysce Biosciences (ENSC) Stock Surges on Patent News - GuruFocus
Ensysce Biosciences (ENSC) Secures $2.2 Million Through Warrant Exercise - GuruFocus
Ensysce Biosciences to raise $2.2 million through warrant exercise By Investing.com - Investing.com Canada
Ensysce Biosciences secures patent for OUD treatment By Investing.com - Investing.com South Africa
Ensysce Biosciences to raise $2.2 million through warrant exercise - Investing.com Australia
Ensysce Biosciences Inc’s Shares Reel: -58.79% Quarterly Revenue Decline Amid 5.62M Market Cap - investchronicle.com
Ensysce Biosciences Stock Doubles In One Trading SessionHere's Why - Yahoo Finance
Dropbox Inc: Weathering Stock Market Storms with 7.92B Market Cap - investchronicle.com
Nuvation Bio Inc Inc. (NUVB) Price Performance: A Technical Analysis Perspective - investchronicle.com
Ensysce Biosciences Raises Fresh $2.2M Capital: H.C. Wainwright Backs Strategic Warrant Deal - Stock Titan
Sabre Corp (SABR) Stock: From Low to High in 52 Weeks - investchronicle.com
Analysts Are Recommending Ensysce Biosciences Inc (ENSC) As A Buy Candidate - Marketing Sentinel
Ensysce Biosciences Inc (NASDAQ:ENSC) stock: You might be surprised - uspostnews.com
Amentum Holdings Inc (AMTM) Shares Are Down -4.43% YTD - Marketing Sentinel
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views - Benzinga
The Psychology of Altria Group Inc Inc. (MO) Price Performance: Understanding Market Sentiment - investchronicle.com
Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval - Stocks Telegraph
The Psychology of Metsera Inc Inc. (MTSR) Price Performance: Understanding Market Sentiment - investchronicle.com
(ENSC) Technical Data - news.stocktradersdaily.com
Safety Shot Inc Inc. (SHOT) Price Performance: A Technical Analysis Perspective - investchronicle.com
Ensysce (ENSC) Advances PF614-MPAR in Overdose Protection Trial - GuruFocus
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Trump's Trade Hints Spark US Equity Gains - Finimize
Ensysce Biosciences secures patent for OUD treatment - Investing.com
Ensysce Biosciences Gets US Patent for Opioid Use Disorder Treatment; Shares Rise Pre-Bell - marketscreener.com
AtlasClear Holdings Inc (ATCH) Stock: A Year of Stock Market Dynamics - investchronicle.com
Revolutionary Opioid Treatment Patent Promises Safer Alternative to Methadone: Key Advantages Revealed - Stock Titan
An In-Depth Look At TPG Inc (TPG) - Marketing Sentinel
DVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Ensysce Biosciences files to sell 652,439 shares of common stock for holders - MSN
ENSC stock touches 52-week low at $1.7 amid market challenges By Investing.com - Investing.com South Africa
ENSC stock touches 52-week low at $1.7 amid market challenges - Investing.com Australia
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
Pre-market Movers: CHRO, QURE, FOTA, LLY... - RTTNews
Ensysce Biosciences (ENSC) Plans to Sell Over 650,000 Shares - GuruFocus
Ensysce Biosciences completes key trial phase for safer opioid - Investing.com
Ensysce Biosciences announces data from opioid overdose protection study - TipRanks
Ensysce Biosciences completes key trial phase for safer opioid By Investing.com - Investing.com India
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Revolutionary Opioid Drug Shows Breakthrough Overdose Protection in Clinical Trial - Stock Titan
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ENSC stock touches 52-week low at $2.11 amid market challenges - Investing.com
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):